Cargando…

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks

AIMS: Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). OBJECTIVES: We assessed the effectiveness and safety of the PCSK9i alir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hollstein, Tim, Kassner, Ursula, Grenkowitz, Thomas, Schumann, Friederike, Bobbert, Thomas, Steinhagen-Thiessen, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838077/ https://www.ncbi.nlm.nih.gov/pubmed/32514867 http://dx.doi.org/10.1007/s40256-020-00411-3

Ejemplares similares

Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report
por: Soll, Dominik, et al.
Publicado: (2019)

Evaluation of the role of STAP1 in Familial Hypercholesterolemia
por: Danyel, Magdalena, et al.
Publicado: (2019)

Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants
por: Kassner, Ursula, et al.
Publicado: (2015)

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
por: Vogt, Anja, et al.
Publicado: (2007)

Statins Aggravate the Risk of Insulin Resistance in Human Muscle
por: Grunwald, Stefanie A., et al.
Publicado: (2022)

Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study
por: Rosada, Adrian, et al.
Publicado: (2020)

A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis
por: Missala, I., et al.
Publicado: (2012)

Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People – Data from the Berlin Aging Study II
por: Buchmann, Nikolaus, et al.
Publicado: (2015)

Phytosterols and Cardiovascular Risk Evaluated against the Background of Phytosterolemia Cases—A German Expert Panel Statement †
por: Windler, Eberhard, et al.
Publicado: (2023)

Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting
por: Schmöcker, Christoph, et al.
Publicado: (2018)

Statinintoleranz und statinassoziierte Muskelschmerzen
por: Stürzebecher, Paulina Elena, et al.
Publicado: (2022)

Knowledge-based best of breed approach for automated detection of clinical events based on German free text digital hospital discharge letters
por: König, Maximilian, et al.
Publicado: (2019)

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis
por: Weylandt, Karsten-H., et al.
Publicado: (2019)

Implementation of integrated geriatric care at a German hospital: a case study to understand when and why beneficial outcomes can be achieved
por: Busetto, Loraine, et al.
Publicado: (2017)

Prevalence of obesity in primary care using different anthropometric measures – Results of the German Metabolic and Cardiovascular Risk Project (GEMCAS)
por: Hauner, Hans, et al.
Publicado: (2008)

Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)
por: Steinhagen-Thiessen, Elisabeth, et al.
Publicado: (2008)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
por: Gürgöze, Muhammed T., et al.
Publicado: (2018)

Real-world use of PCSK9 inhibitors: A single-center experience
por: Sarsam, Sinan, et al.
Publicado: (2018)

ANTECEDENTS, OUTCOMES, AND CORRELATES OF METABOLIC HEALTH IN OLDER AGE: A MULTIDISCIPLINARY PERSPECTIVE
por: Drewelies, Johanna, et al.
Publicado: (2022)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Challenges with PCSK9 Inhibitors Use in Asia Given Real-World Data Implications
por: Uno-Eder, Kiyoko
Publicado: (2023)

The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment
por: März, Winfried, et al.
Publicado: (2023)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
por: Puccini, Marianna, et al.
Publicado: (2022)

PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network
por: Chamberlain, Alanna M., et al.
Publicado: (2019)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
por: Feng, Zhen, et al.
Publicado: (2022)

Patient behaviour in medication management: Findings from a patient usability study that may impact clinical outcomes
por: Schenk, Ariane, et al.
Publicado: (2019)

Validation of a Laser Ranged Scanner-Based Detection of Spatio-Temporal Gait Parameters Using the aTUG Chair
por: Fudickar, Sebastian, et al.
Publicado: (2021)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Patient Involvement in Geriatric Care – Results and Experiences from a Mixed Models Design Study within Project INTEGRATE
por: Kiselev, Joern, et al.
Publicado: (2018)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Physical activity and cohabitation status moderate the link between diabetes mellitus and cognitive performance in a community-dwelling elderly population in Germany
por: Fink, Anne, et al.
Publicado: (2017)

Problematic drinking in the old and its association with muscle mass and muscle function in type II diabetes
por: Buchmann, Nikolaus, et al.
Publicado: (2019)

Potentially inappropriate medication in older participants of the Berlin Aging Study II (BASE-II) – Sex differences and associations with morbidity and medication use
por: Toepfer, Sarah, et al.
Publicado: (2019)

Plasma carotenoids, tocopherols and retinol - Association with age in the Berlin Aging Study II
por: Weber, Daniela, et al.
Publicado: (2020)

Low muscle strength and increased arterial stiffness go hand in hand
por: König, Maximilian, et al.
Publicado: (2021)

LP(A) AND METABOLIC SYNDROME IN OLDER PEOPLE
por: Buchmann, Nikolaus, et al.
Publicado: (2022)

ASSOCIATIONS AMONG LATENT FACTORS OF METABOLIC LOAD, BRAIN VOLUME, AND COGNITION IN HEALTHY AGING
por: Duezel, Sandra, et al.
Publicado: (2022)

Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a)
por: Schwarz, Andrea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o0a7edogoi2ccrehrfj2m87n65